The obscure advisory committees at the heart of the U.S. drug pricing debate
Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly and Co and Teva Pharmaceutical Industries.
from Reuters: U.S. https://reut.rs/2VwZsGQ
from Reuters: U.S. https://reut.rs/2VwZsGQ
The obscure advisory committees at the heart of the U.S. drug pricing debate
![The obscure advisory committees at the heart of the U.S. drug pricing debate]()
Reviewed by shada
on
April 30, 2019
Rating: